This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name : 
LifeSpan Biosciences
product type : 
antibody
product name : 
Macrophage Antibody LS-C195932
catalog : 
LS-C195932
clonality : 
polyclonal
host : 
domestic rabbit
conjugate : 
nonconjugated
product information
AntibodyID : 
203935
AntibodyName : 
LS-C195932
TargetSpecies : 
Rat
Host Species : 
Rabbit
Product Name : 
Macrophage Antibody LS-C195932
Specificity : 
Rat Macrophage
ClonalityDesc : 
Polyclonal
AntibodyModification : 
Unconjugated
PresentationDesc : 
Sterile-filtered liquid, no preservatives
ImmunogenType : 
Cells
ImmunogenDesc : 
Rat macrophages.
PurificationDesc : 
Ion exchange chromatography
RecommendedStorageDesc : 
Store at -20°C.
IsotypeName : 
IgG
Gene : 
Macrophage
Reactivity : 
Rat
ShortWebDescription : 
Macrophage antibody LS-C195932 is an unconjugated rabbit polyclonal antibody to rat Macrophage.
Synonyms : 
, Mature Macrophage Marker
SalesRegion : 
Worldwide
company information
LifeSpan Biosciences
2401 Fourth Avenue, Suite 900
Seattle, WA 98121
Seattle, WA 98121
CustomerSupport@lsbio.com
https://www.lsbio.com1-206-464-1554
headquarters: USA
Since 1995, LifeSpan has been the industry leader in molecular pathology, specializing in the localization of proteins in normal and diseased tissues, both human and non-human.  We offer more than 74,000 antibodies, custom designed immunohistochemistry (IHC) studies, immediately available human tissue IHC profiles for more than 500 proteins, and histology and pathology services.  Our bank of 2 million specimens is available to support our customers' contract research studies and contains frozen and formalin-fixed (FFPE) normal and diseased tissues. Our contract services are comprehensive; they include study design, antibody sourcing and characterization, tissue sourcing and validation, immunolabeling, trouble shooting, and interpretation of the results by a LifeSpan pathologist.
questions and comments
